Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?

POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?

Presented by
Prof. Solange Peters, Lausanne University, Switzerland
Conference
WCLC 2022
Trial
Phase 3, POSEIDON
Doi
https://doi.org/10.55788/b24ddb43
    An exploratory analysis of the phase 3 POSEIDON trial showed that first-line treatment with tremelimumab plus durvalumab plus chemotherapy was efficacious in subgroups of patients with metastatic non-small cell lung cancer (NSCLC) that are usually associated with poor responses to immunotherapy, including those with KEAP1, KRAS, and STK11 mutations [1].

    In patients with EGFR/ALK wildtype metastatic NSCLC, the combination of tremelimumab, durvalumab, and chemotherapy outperformed chemotherapy alone regarding progression-free survival (PFS) and overall survival (OS), primary results from the phase 3 POSEIDON trial (NCT03164616) displayed (n=1,003) [2]. However, it was unknown whether this combination treatment was beneficial for patients with STK11, KEAP1, or KRAS mutations. Therefore, Prof. Solange Peters (Lausanne University, Switzerland) and co-investigators performed an exploratory analysis of outcomes from the POSEIDON trial by mutational status.

    Participants with STK11 mutations appeared to have an OS benefit if they were treated with the experimental treatment (n=31) instead of chemotherapy alone (n=22; median OS 15.0 vs 10.7 months; HR 0.56; 95% CI 0.56–1.03). Similarly, there was a clear trend towards an OS benefit of the experimental treatment over chemotherapy alone in those with KEAP1 mutations (median OS 13.7 vs 8.7 months; HR 0.43; 95% CI 0.16–1.25). However, the sample size of patients with KEAP1 mutations was small, with only 22 patients who followed the experimental treatment and 6 patients who received chemotherapy alone. Furthermore, patients with KRAS-mutated non-squamous cell histology had a longer median OS if they received tremelimumab, durvalumab, and chemotherapy (n=60) than if they received chemotherapy alone (n=53; median OS 25.7 vs 10.4 months; HR 0.56; 95% CI 0.36–0.88). PFS data and objective response rates demonstrated similar trends of efficacy in these subgroups.

    According to Prof. Peters, this data suggests that the combination therapy of tremelimumab, durvalumab, and chemotherapy is as a potential first-line treatment for harder-to-treat subgroups of patients with metastatic NSCLC.

    1. Peters S, et al. Association between KRAS/STK11/KEAP1 mutations and outcomes in POSEIDON: durvalumab ± tremelimumab + chemotherapy in mNSCLC. OA15.04, WCLC 2022, Vienna, Austria, 06–09 August.
    2. Johnson M, et al. PL02.01, WCLC 2021, 08–14 September.

     

    Copyright ©2022 Medicom Medical Publishers



    Posted on